- Home
- NTRB vs CNTX Comparison
NTRB vs CNTX Comparison
Compare NTRB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- CNTX
- Stock Information
- Founded
- NTRB 2016
- CNTX 2015
- Country
- NTRB United States
- CNTX United States
- Employees
- NTRB N/A
- CNTX N/A
- Industry
- NTRB Industrial Specialties
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- CNTX Health Care
- Exchange
- NTRB Nasdaq
- CNTX Nasdaq
- Market Cap
- NTRB 71.8M
- CNTX 75.6M
- IPO Year
- NTRB N/A
- CNTX 2021
- Fundamental
- Price
- NTRB $7.15
- CNTX $0.84
- Analyst Decision
- NTRB Buy
- CNTX Strong Buy
- Analyst Count
- NTRB 1
- CNTX 5
- Target Price
- NTRB $13.00
- CNTX $5.25
- AVG Volume (30 Days)
- NTRB 33.0K
- CNTX 151.3K
- Earning Date
- NTRB 09-09-2025
- CNTX 11-05-2025
- Dividend Yield
- NTRB N/A
- CNTX N/A
- EPS Growth
- NTRB N/A
- CNTX N/A
- EPS
- NTRB N/A
- CNTX N/A
- Revenue
- NTRB $2,578,059.00
- CNTX N/A
- Revenue This Year
- NTRB $560.75
- CNTX N/A
- Revenue Next Year
- NTRB $588.39
- CNTX N/A
- P/E Ratio
- NTRB N/A
- CNTX N/A
- Revenue Growth
- NTRB 42.92
- CNTX N/A
- 52 Week Low
- NTRB $2.98
- CNTX $0.49
- 52 Week High
- NTRB $9.42
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- NTRB 59.09
- CNTX 53.78
- Support Level
- NTRB $5.85
- CNTX $0.81
- Resistance Level
- NTRB $7.48
- CNTX $0.89
- Average True Range (ATR)
- NTRB 0.43
- CNTX 0.05
- MACD
- NTRB 0.12
- CNTX -0.01
- Stochastic Oscillator
- NTRB 80.26
- CNTX 25.00
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.